Eli Lilly and Company’s Effient Tied in Study to Higher Rate of Cancer Risk Than Plavix

Bloomberg -- Eli Lilly’s blood-thinner Effient was linked to higher rates of cancer than Bristol-Myers Squibb Co.’s rival product Plavix, research published today found.